Darzalex Faspro® (daratumumab/hyaluronidase-fihj), Kyprolis® (carfilzomib) – Expanded indication
December 1, 2021 - The FDA approved Janssen’s Darzalex Faspro (daratumumab/hyaluronidase-fihj) and Amgen’s Kyprolis (carfilzomib), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Top